The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis
Corresponding Author
Kostantinos Zarogoulidis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Fax: +30-2310-992433.
Kostantinos Zarogoulidis, Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Nikos K. Karamanos, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorEufimia Boutsikou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorPavlos Zarogoulidis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorEllada Eleftheriadou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorTheodore Kontakiotis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorHellie Lithoxopoulou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorGeorge Tzanakakis
Department of Histology, School of Medicine, University of Crete, Herakleion, Greece
Search for more papers by this authorIoannis Kanakis
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorCorresponding Author
Nikos K. Karamanos
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Fax: +30-2610-997153.
Kostantinos Zarogoulidis, Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Nikos K. Karamanos, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorCorresponding Author
Kostantinos Zarogoulidis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Fax: +30-2310-992433.
Kostantinos Zarogoulidis, Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Nikos K. Karamanos, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorEufimia Boutsikou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorPavlos Zarogoulidis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorEllada Eleftheriadou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorTheodore Kontakiotis
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorHellie Lithoxopoulou
Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Search for more papers by this authorGeorge Tzanakakis
Department of Histology, School of Medicine, University of Crete, Herakleion, Greece
Search for more papers by this authorIoannis Kanakis
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorCorresponding Author
Nikos K. Karamanos
Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Fax: +30-2610-997153.
Kostantinos Zarogoulidis, Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece
Nikos K. Karamanos, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
Search for more papers by this authorAbstract
Bone metastases occur in 20–40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa®), a 3rd generation BP, with a focus on the survival, time to progression and pain effect in lung cancer patients with bone metastases. Lung cancer patients (n = 144, Stage IV) with evidence of metastasis bone scan were included. Eighty-seven of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 patients received no ZOL (Group B). All patients were treated with a combination chemotherapy consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6. It was found that Group A had a statistically significant longer survival (p < 0.01) when compared to Group B. A statistically significant positive correlation was found between the number of cycles of therapy with ZOL and total patient survival (p < 0.01, Pearson correlation) and time to progression (p < 0.01). Pain effect of ZOL had no significant difference between the 2 groups of patients (p > 0.05). Urine N-telopeptide of type I collagen (NTx) levels decreased in patients with NTx ≤ 29 nM BCE/mM creatinine at baseline after treatment with ZOL. The results of our study suggest that the addition of ZOL increases overall survival in lung cancer patients with bone metastases. The longer period of receiving ZOL, the better effect on survival and time to progression. © 2009 UICC
References
- 1 Koshimune R,Aoe M,Toyooka S,Hara F,Ouchida M,Tokumo M,Sano Y,Date H,Shimizu N. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. Cancer 2007; 12: 7–8.
- 2
Coleman RE.
Skeletal complications of malignancy.
Cancer
1997;
80:
1588–94.
10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- 3 Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 1218–25.
- 4 Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42: 895–906.
- 5 Kohno N,Aogi K,Minami H,Nakamura S,Asaga T,Iino Y,Watanabe T,Goessl C,Ohashi Y,Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314–21.
- 6 Rosen LS,Gordon D,Kaminski M,Howell A,Belch A,Mackey J,Apffelstaedt J,Hussein MA,Coleman RE,Reitsma DJ,Chen BL,Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735–44.
- 7
Rogers MJ,Watts DJ,Russel RG.
Overview of bisphosphonates.
Cancer
1997;
80:
1652–60.
10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 8 Coleman RE. Management of bone metastases. Oncologist 2000; 5: 463–70.
- 9 Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97 ( Suppl 3): 840–7.
- 10 Matsumoto S,Kimura S,Segawa H,Kuroda J,Yuasa T,Sato K,Nogawa M,Tanaka F,Maekawa T,Wada H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines. Lung Cancer 2005; 47: 31–9.
- 11 Berger W,Kubista B,Elbling L,Sutterluty H,Micksche M. The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 2005; 46 (Abst 4981) AACR Meeting Abstracts 2005:1176-c.
- 12 Demers LM,Costa L,Chinchilli VM,Gaydos L,Curley E,Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 1489–94.
- 13 Brown JE,Cook RJ,Major P,Lipton A,Saad F,Smith M,Lee KA,Zheng M,Hei YJ,Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59–69.
- 14 Lipton A,Costa L,Ali SM,Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001; 27: 181–5.
- 15 Costa L,Demers LM,Gouveia-Oliveira A,Schaller J,Costa EB,de Moura MC,Lipton A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20: 850–6.
- 16 Demers LM,Costa L,Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88: 2919–26.
- 17 Vinholes JJ,Purohit OP,Abbey ME,Eastell R,Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243–50.
- 18Available at: http://www.zometa.com/around-the-world/european-product-characteristics.jsp.
- 19 Aapro M,Abrahamsson PA,Body JJ,Coleman RE,Colomer R,Costa L,Crinò L,Dirix L,Gnant M,Gralow J,Hadji P,Hortobagyi GN, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420–32.
- 20 Berenson J,Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004; 9: 319–29.
- 21 Cleeland CS,Ryan KM. Bone pain inventory. Ann Acad Med Singapore 1994; 23: 129–38.
- 22 Ibrahim T,Barbanti F,Giorgio-Marrano G,Mercatali L,Ronconi S. Oncologist 2008; 13: 330–6.
- 23 Jagdev SP,Coleman RE,Shipman CM,Rostami HA,Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–34.
- 24 Neville-Webbe HL,Evans CA,Coleman RE,Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92–103.
- 25 Vogt U,Bielawski KP,Bosse U,Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12: 1109–14.
- 26 Coleman RE,Major P,Lipton A,Brown JE,Lee KA,Smith M,Saad F,Zheng M,Hei YJ,Seaman J,Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4821–2.
- 27 Caraglia M,Santini D,Marra M,Vincenzi B,Tonini G,Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 7–26.
- 28 Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007; 6: 305–13.
- 29 Rosen LS,Gordon D,Tchekmedyian NS,Yanagihara R,Hirsh V,Krzakowski M,Pawlicki M,De Souza P,Zheng M,Urbanowitz G,Reitsma D,Seaman J. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in pts with nonsmall cell lung carcinoma and other solid tumors: arandomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613–21.
- 30 Guarneri V,Donati S,Nicolini M,Giovanelli S. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842–8.
- 31 Ali SM,Esteva FJ,Hortobagyi G,Harvey H,Seaman J,Knight R,Costa L,Lipton A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434–7.
Citing Literature
